SCHEMBL700234

SCHEMBL700234

COC(=O)c1ccc(F)c(-c2ccc(C=C3C(=O)Nc4ccc(Cl)cc43)o2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 8/20 0.66
PIM2 Q9P1W9 8/20 0.66
PSEN1 P49768 1/20 0.54
PSEN2 P49810 1/20 0.54
APH1B Q8WW43 1/20 0.54
NCSTN Q92542 1/20 0.54
APH1A Q96BI3 1/20 0.54
PSENEN Q9NZ42 1/20 0.54
PDPK1 O15530 1/20 0.52
AURKA O14965 1/20 0.51
RAF1 P04049 1/20 0.51
SIRT2 Q8IXJ6 1/20 0.50
FLT3 P36888 2/20 0.49
PIM3 Q86V86 1/20 0.49
LRRK2 Q5S007 3/20 0.48
PIK3CA P42336 1/20 0.48
PIK3CG P48736 1/20 0.48
RPS6KA3 P51812 1/20 0.47
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700233 1.00 PIM1 (0.66) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL702072 0.94 PIM1 (0.59) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL702071 0.94 PIM1 (0.59) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL700261 0.89 PIM1 (0.68) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL700262 0.89 PIM1 (0.68) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL701912 0.82 PIM1 (0.60) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL701913 0.82 PIM1 (0.60) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL700867 0.80 PIM1 (1.00) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL700868 0.80 PIM1 (1.00) PIM1PIM2PSEN1PSEN2APH1B
SCHEMBL10091752 0.80 PIM1 (1.00) PIM1PIM2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885PSEN1 1780/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885PSEN1 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.